Treatments Articles

Articles

  • Declining use of radical prostatectomy and pelvic lymphadenectomy despite more robotics: National population data over 15 years.

    To describe national surgical patterns of prostate cancer (PCa) care considering radical prostatectomy with or without pelvic lymphadenectomy and consideration of robotic-assisted techniques.

    Retrospective analysis of publicly accessible Medicare claims data was performed for the period 2001-2016 and included patients undergoing radical prostatectomy with or without pelvic lymphadenectomy relative to total and PCa-specific populations among men aged 45-84 years.

    Published May 7, 2019
  • Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.

    The objective of this study was to compare the overall survival of patients who undergo radical prostatectomy or radiotherapy versus noncancer controls to discern whether there is a survival advantage according to prostate cancer treatment and the impact of selection bias on these results.

    Published January 26, 2017
  • Editorial and Advertising Guidelines

    scale and gavel

    Introduction

    UroToday® connects global clinicians, interested in the specialty of urology, to one of the most extensive urological disease news and information archives available in one site. The site is committed to delivering the information healthcare professionals need to save time and stay up-to-date on emerging evidence that supports clinical practice decisions towards improving patient outcomes.

    As an independent urological information services company, UroToday adheres to the highest standards of integrity in medical communications in its production and distribution of published information services.  The content is comprised of unbiased urological health news and information written by practicing healthcare providers.

    Editorial Guidelines

    The editorial mission is to provide accurate, timely, unbiased and evidence-based information about urological diseases and treatments. All editorial content is produced independently and without influence of advertisers or commercial supporters. The editorial team reserves the right to reject any advertising campaign or promotion it deems misleading or controversial. Physician reviewers are not provided information about advertisers or commercial supporters of the information they review. Original content contains writer bylines, and members of the editorial team are charged with reporting any conflicts of interest in all content. All articles are reviewed and approved by the editorial team of urologists.

    Advertising Guidelines

    Paid advertisements are clearly labeled as such to distinguish them from editorial content. Display of an advertisement does not imply an endorsement of such product, nor does it imply that UroToday performed due diligence on such products. Pharmaceutical and device advertisements must comply with US Food and Drug Administration (FDA) regulations as well as regulations and laws in the localities in which they are viewed. Continuing Medical Education (CME) articles and  CME posttests, as displayed on a single computer screen, appear ad-free when viewed by a clinician - in compliance with Accreditation Council for Continuing Medical Education (ACCME) guidelines. Banner and similar ads may immediately redirect users from UroToday's content and website to content and websites that are independent of UroToday and are not controlled by or necessarily reflect UroToday's policies regarding editorial independence, advertising, privacy, or any other policy. While UroToday may agree to develop and write content funded by a separate entity, any commercially supported content is clearly labeled. Its editorial team continues to maintain editorial independence and control when producing and publishing any commercially supported content.

    Questions about UroToday’s editorial and advertising policies should be directed to .

    UroToday will continually update its Editorial and Advertising Guidelines to reflect ongoing policy changes.

    Published January 2, 2015
  • How can we develop a more clinically useful and robust algorithm for diagnosing and treating nocturia? ICI-RS 2017.

    Nocturia, or waking up at night to void, is a highly prevalent and bothersome symptom. Currently, there is a lack of clear and consistent recommendations regarding evaluation and management of nocturia.

    Published August 27, 2018
  • Optimal Management of Non-Muscle Invasive Micropapillary Variant Urothelial Carcinoma: Possibility For Missed Chance at Cure?

    Bladder cancer is a common disease in the US, affecting upwards of 74,000 patients yearly (1) . Micropapillary bladder carcinoma (MPBC) is a sub type variant which was described in 1994 from our institution and which has gained in recognition since then.

    Published March 1, 2016
  • Patient characteristics and treatments one year after diagnosis of renal cancer in 2015 according to the presence or absence of metastasis and a history of another tumour: A national observational study.

    This study describes the characteristics, management and outcome of patients one year after a diagnosis of renal cancer, according to the presence of a history of another tumour and metastases at diagnosis or during the first year.

    Published May 23, 2019
  • Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States.

    PURPOSE - To examine diagnostic tests and treatment patterns in men with new onset benign prostatic hyperplasia (BPH) using consolidated national electronic health record (EHR) data.

    MATERIALS AND METHODS - The Humedica(®) EHR database consists of de-identified patient records from approximately 25 million patients in the US.

    Published March 2, 2016
  • Population-based assessment of determining predictors for quality of prostate cancer surveillance.

    Despite recent interest in the overdiagnosis and overtreatment of prostate cancer, the acceptance of expectant management for patients with indolent prostate cancer has remained slow. Moreover, the intensity of surveillance strategies remains to be elucidated.

    Published September 1, 2015
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe